# Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System

> **NCT05165602** · — · UNKNOWN · sponsor: **Peking University** · enrollment: 30 (estimated)

## Conditions studied

- HER2 Positive Gastric Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05165602
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-01
- **Primary completion:** 2023-05-01
- **Final completion:** 2023-05-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2021-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05165602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05165602, "Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05165602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*